echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Bristol-Myers Squibb reaches cooperation with US$1.9 billion to promote the development of regulatory T cell therapy

    Bristol-Myers Squibb reaches cooperation with US$1.9 billion to promote the development of regulatory T cell therapy

    • Last Update: 2022-08-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ▎Edited by WuXi AppTec Content Team

    GentiBio today announced a collaboration with Bristol-Myers Squibb (BMS) to co-develop novel engineered regulatory T cells (Treg) to help rebuild immune tolerance and repair tissue in patients with inflammatory bowel disease (IBD)



    Inflammatory bowel disease is a debilitating and life-threatening chronic inflammation of the gastrointestinal tract


    [1] GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases.


    [2] BMS Bets up to $1.



    Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.